AXOGEN CORP (AXGN) Downgraded by Zacks to NEUTRAL

Zacks Zacks Investment Research downgraded shares of AXOGEN CORP (AXGN) from OUTPERFORM to NEUTRAL on January 19, 2015, with a target price of $4.50.

AxoGen Corp. is a regenerative medicine company engaged in the development and commercialization of technologies for peripheral nerve reconstruction and regeneration. It offers products for the repair of peripheral nerve injuries. AxoGen Corp was formerly known as LecTec Corporation.

Get all Zacks Research Reports and be alerted to fast-breaking buy and sell opportunities every trading day.

To get a free copy of the research report on AXOGEN CORP (AXGN),
click here.
For more information about research offerings from Zacks Investment Research, visit
Zacks.com .

Be the first to comment

Leave a Reply